With 60 000 fatalities per year, colorectal cancer is second only to lung cancer as a cause of cancer mortality in the United States. Each year, 150 000-160 000 new colorectal cancers are diagnosed, of which 10%-20% already have liver metastases. Ultimately, about 70% of all colorectal cancer patients develop liver metastases (1, 2) . Hepatic resection is currently the only form of treatment that offers long-term survival, with 5-year survival rates ranging from 25% to 39% (3) (4) (5) . With the use of current indications for hepatectomy, only 10%-20% of all patients are candidates for curative surgery (1, 2) . The prognosis for the remaining patients is grim because palliative chemotherapy and symptomatic treatments are the only available options.
Interleukin 12 (IL-12) is a cytokine known to enhance the cytolytic activity of natural killer (NK) cells, lymphokineactivated killer cells, T cells, and macrophages (6) (7) (8) (9) . It promotes cellular immune response by facilitating the proliferation and activation of T-helper (Th1) cells (10) and stimulates the proliferation of activated NK cells (6, 8, 11 ). Antigen-presenting cells (12) , such as dendritic cells (13) , macrophages, and B lymphocytes, mainly produce IL-12, which mediates the antitumor activity partially by stimulating the production of interferon gamma (IFN ␥) from NK and T cells (14) (15) (16) . In a previous study (17) , we have shown that in vivo adenovirusmediated IL-12 (ADV/IL-12) gene transfer to established hepatic metastases induced a substantial reduction in tumor volume and a prolonged survival of treated animals compared with that of control animals. A small fraction of IL-12-treated animals was cured of their tumor and achieved long-term survival after tumor cell inoculation. NK cells were the early and major effector cells responsible for the survival benefit of IL-12-treated animals (18) . Substantial initial tumor reduction, but no long-term survival, was achieved with IL-12 treatment in a study performed in tumor-bearing T-celldepleted syngeneic animals and T-celldeficient nude mice. These studies demonstrated that NK cells alone are essential for early immune rejection of tumor cells, but participation of T cells is required for long-term antitumor systemic immunity (18) .
4-1BB ligand (4-1BBL) is a type II surface glycoprotein belonging to the tumor necrosis factor superfamily (19, 20) . Expression of 4-1BBL is restricted to the antigen-presenting cells, such as dendritic cells, macrophages, and activated B cells (21, 22) . This ligand interacts with its receptor (4-1BB) expressed on the surface of primed CD4+ and CD8+ T cells (23, 24) in addition to T-cell receptor engagement and induces expansion, especially of CD8+ T cells (25) . Enhanced 4-1BB/4-1BBL interaction has been shown to amplify T-cell-mediated immunity (26) . Furthermore, systemic administration of agonistic anti-4-1BB antibodies can eradicate established subcutaneous tumors in mice (27) through activation of both CD4+ and CD8+ T cells.
In this study, we took a gene therapy approach to the problem and tested the antitumor consequences of intratumoral delivery of IL-12 and 4-1BBL genes. We used a syngeneic mouse model of liver metastases induced by a colon cancer cell line. We then analyzed the immune mechanisms underlying this combination treatment.
METHODS
Cell cultures. MCA26 cells (28) , a chemically induced colon carcinoma line of low immunogenicity derived from a BALB/c background, were grown and maintained in high glucose minimum essential medium/Ham's Medium F-12 (Sigma Chemical Co., St. Louis, MO). The 293 cells (adenoviral E1-transformed human embryonic kidney cells; American Type Culture Collection [ATCC)], Manassas, VA) were maintained in Dulbecco's modified Eagle medium (Sigma Chemical Co.) (29) . Culture media were supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin (Sigma Chemical Co.).
Recombinant adenoviral vectors. Construction of a replication-defective adenoviral vector bearing the murine IL-12 under the transcriptional control of the Rous sarcoma virus-long terminal repeat (RSV-LTR) promoter has been previously reported (17) . pfu (n ‫ס‬ 11), and 4) ADV/DL312 at 1 × 10 9 pfu (n ‫ס‬ 10). The recombinant adenoviruses were injected in 50-L volumes of 10 mM Tris-HCl (pH 7.4) containing 1 mM MgCl 2 /10% (vol/vol) glycerol and Polybrene (20 mg/mL) (all from Sigma Chemical Co.). Long-term survival and tumor response studies were performed to assess treatment outcome. For tumor response studies, the animals were killed 14 days after virus injection, and tumor diameters were measured. Tumor volume was calculated with the use of the following formula: a × b 2 /2, where a ‫ס‬ the largest diameter and b ‫ס‬ the smallest diameter (31) .
Study of the immune cell subsets involved in the gene therapy with ADV/IL-12 and ADV/4-1BBL. A long-term survival study of tumor-bearing animals treated with the combination ADV/IL-12 (1 × 10 8 pfu) and ADV/4-1BBL (1 × 10 9 pfu) was performed, with or without specific depletion of NK cells (with anti-asialo GM1 antibody treatment; Wako Pure Chemical Industries, Ltd., Richmond, VA) (32), depletion of CD4+ T cells (with GK 1.5 antibody treatment; ATCC) (33) , or depletion of CD8+ T cells (with 2.43 antibody; ATCC) (34) . A combination of rabbit IgG (Accurate Chemical and Scientific Corporation, Westbury, NY) and rat IgG (Caltag Laboratories, Burlingame, CA) was used in the control animals. The cell depletion was started the day before gene therapy delivery. Mice were given 50-100 g of antibody intraperitoneally per depletion per day. Antibodies for control or NK cell depletion were administered for 5 consecutive days and then every 5th day afterward for the duration of the experiment. Purified ascites fluid containing GK 1.5 or 2.43 antibodies was administered three times every other day, beginning 1 day before gene therapy delivery, and then every 5th day for the duration of the experiment. The efficacy of the immune subset depletion (>99%) with the use of these antibodies was confirmed by flow cytometry.
Challenge experiments with parental tumor cells. Long-term (>120 days) surviving animals treated by use of a gene therapy protocol with the combination IL-12 and 4-1BBL were given subcutaneous injections of 7 × 10 4 MCA26 parental tumor cells in 100 L Hanks' balanced salt solution. Growth pattern and size of tumors were monitored. In vivo NK cell depletion (by administration of antiasialo GM1 antibody) or total T-cell depletion (by administration of anti-Thy1.2 antibody, 53-6.72; ATCC) was performed in two different groups of long-term surviving mice. A combination of rabbit IgG and rat IgG was used in control long-term surviving animals. The schedule of antibody administration has been described in the prior experiment. "Naive" BALB/c mice that have never been exposed to MCA26 cells were used to assess the growth of a subcutaneous MCA26 tumor.
Statistical analysis. The Wilcoxon rank-sum test was used to compare tumor responses in the different experimental groups. The survival of animals in long-term studies was estimated by the KaplanMeier method. Comparisons of survival curves of different groups were made by the log-rank test. To analyze the results of the kinetic study of subcutaneous tumor growth after challenge with parental tumor cells of mice with long-term survival after gene therapy treatment, the following method was applied: For each animal, the average total tumor volume (ATTV) was calculated from day 6 to day 27. The ATTV equals the area under the curve (AUC) of the tumor volumes over time divided by the number of days (ATTV ‫ס‬ AUC/number of days ‫ס‬ AUC/27 -6 ‫ס‬ AUC/21). The ATTV represents the average height of the volume-time curve from day 6 to day 27, thereby giving an overall index of tumor size (34) . Comparisons of ATTVs between two groups were performed by the Dunn multiple comparisons procedure for the Kruskal-Wallis test on the basis of four groups (35) . All multiple comparisons for four groups in this article consisted of three comparisons (usually made up of a control group along with three treatment groups). Hence, to ensure an overall type I error rate of .05, each comparison was declared to be statistically significantly different if the P value was less than .05/3 ‫ס‬ .017. All P values were two sided. (Fig. 1, A) . To assess the in vivo effect of the 4-1BBL alone, an in vivo tumor response study was performed (Fig. 1, B) . The sizes of MCA26 cell-induced liver tumors were compared 14 days after intratumoral administration of 2 × 10 9 pfu/ animal of ADV/4-1BBL (n ‫ס‬ 17) or ADV/DL312 (n ‫ס‬ 17). The median tumor volume (range) was 252 (32-1368) mm 3 in the ADV/4-1BBL-treated group and 968 (108-2304) mm 3 in the ADV/ DL312-treated group (P ‫ס‬ .023, Wilcoxon rank-sum test).
RESULTS

Assessment of ADV/4-1BBL Transgene Expression
Long-Term Remission of Liver Metastases
The potential of the combined treatment with 4-1BBL and IL-12 for controlling tumor growth and for increasing the long-term survival of the animals was studied. Mice bearing tumors measuring between 4 × 4 and 6 × 6 mm were randomly assigned to one of four groups (n ‫ס‬ 9-13 animals/group): 1) ADV/IL-12 plaque-forming units/animal) (n ‫ס‬ 17 mice/group). Animals were killed 14 days after virus injection, and the tumor size was measured. The median tumor volume was 252 (range, 32-1368) mm 3 and 968 (range, 108-2304) mm 3 for the 4-1BBL and DL312 groups, respectively (P ‫ס‬ .023, Wilcoxon rank-sum test). Vertical bars represent 95% confidence intervals. 9 pfu) (n ‫ס‬ 10). The viral vectors were injected directly into the tumor. Eight (62%) of 13 animals in the group treated with the combination of IL-12/4-1BBL compared with two (22%) of nine animals in the IL-12 group were alive at 120 days after tumor inoculation (P ‫ס‬ .015, log-rank test). All of the animals in the 4-1BBL-and DL312-alone groups died between 20 and 40 days (compared with the combination treatment group; P ‫ס‬ .0001, log-rank test). Vertical bars represent 95% confidence intervals. days after tumor inoculation (P ‫ס‬ .015, log-rank test).
Requirements of Both NK Cells and CD8+ T Cells for Long-Term Antitumor Immunity
To study the effector cells that are responsible for the antitumor immunity generated by the combination ADV/IL-12 plus ADV/4-1BBL treatment, an in vivo depletion experiment was conducted (Fig.  3) . All of the animals in the NK celldepletion (n ‫ס‬ 10) and CD8 celldepletion (n ‫ס‬ 10) groups died between 20 and 30 days after tumor implantation because of tumor progression at the liver and at distant sites. Mice in the CD4 celldepletion (n ‫ס‬ 8) and the control Ig (n ‫ס‬ 8) groups showed no difference in longterm survival (P ‫ס‬ .6, log-rank test). The differences observed between control Ig and NK and control Ig and CD8 celldepletion groups are statistically significant (P ‫ס‬ .0003 and .002, respectively; log-rank test). Those results indicate that both NK cells and CD8+ T cells are required for the long-term tumor remission induced by the IL-12/4-1BBL gene therapy.
Persistence of Long-Term Systemic Antitumor Immunity
To test the persistence of a systemic antitumor immunity, long-term (>120 days) surviving animals after gene therapy were challenged with a subcutaneous injection of parental MCA26 tumor cells. The tumor growth was observed for a 4-week period in four groups of animals: 1) naive mice (n ‫ס‬ 7), 2) NK celldepleted mice (n ‫ס‬ 9), 3) T-cell-depleted mice (n ‫ס‬ 5), and 4) control Ig-treated mice (n ‫ס‬ 7). Mice from groups 2-4 were long-term surviving animals after gene therapy treatment with the combination IL-12 and 4-1BBL. One hundred percent of T-cell-depleted and naïve mice formed a tumor. Compared with the control Ig group (one [14.3%] of seven formed a tumor), the percentages of mice with tumor formation in T-cell-depleted and naive animals were statistically significantly higher (P ‫ס‬ .015 and .005, respectively; Fisher's exact test). In the NK celldepleted group, 77.7% (seven of nine) of the animals grew tumors, while only 14.2% (one of seven) mice in the control Ig-treated group did so (Fig. 4, A) (P ‫ס‬ .041, not significant tumor progression; Fisher's exact test). The mean tumor volumes calculated as ATTV for different groups at different time points are shown in Fig. 4 , B. The differences in ATTV observed between the control Igtreated group and the T-cell-depleted and naive groups are statistically significant (P<.002 level, Dunn multiple comparisons procedure for the Kruskal-Wallis test). The difference between control Igtreated and NK cell-depleted groups is not statistically significant after adjustment for multiple comparisons. To test systemic antigenic specificity by use of the same experimental design, naive mice and long-term surviving mice after ADV/IL-12/ADV/4-1BBL combination treatment were challenged with a subcutaneous injection of unrelated JC breast cancer cells. One hundred percent of naive mice (n ‫ס‬ 7) and 75% of long-term surviving mice (n ‫ס‬ 8) formed a JC tumor (P = .47, Fisher's exact test). These results confirm the presence of a specific antitumor immune response in the combination-treated animals.
DISCUSSION
In a previous study (17) , we have shown the efficacy of intratumoral administration of ADV/IL-12 monotherapy in a colon cancer liver metastases model with respect to tumor regression and survival advantages. Nevertheless, 75% of ADV/ IL-12-treated animals died secondary to tumor progression. IL-12 was found to induce a strong tumor-specific NK cell response leading to initial tumor regression (18) . T-cell activation, however, being essential for long-term antitumor immunity, in addition to the observed NK cell stimulation, was found only in 25% of the ADV/IL-12-treated animals, which showed long-term survival (>120 days after tumor inoculation) (18) . Conversely, animals that did not have T-cell activation died within 50 days after tumor implantation.
Therefore, in this study, we tested the potential of an adenoviral-mediated intratumoral gene transfer of the combination IL-12 and 4-1BBL, a powerful T-cell costimulatory molecule, in an orthotopic tumor model of metastatic colon carcinoma.
4-1BBL alone may have induced a Tcell-mediated antitumor immune response that led to a statistically significant delay in tumor growth. However, this T-cellmediated antitumor response did not persist, and all of the animals treated with 4-1BBL alone eventually died 30-40 days after tumor inoculation. In combination with IL-12, 4-1BBL may have induced a stronger stimulation and proliferation of T cells. The combination treatment led to a statistically significant higher percentage of long-term surviving animals and the development of a potent antitumor sys- T-cell-depleted and control Ig-treated animals showed comparable long-term survival without statistically significant difference (P ‫ס‬ .6, log-rank test). The differences between the control Ig group and the NK-or CD8-depleted groups, however, are statistically significant (P ‫ס‬ .0003 and .002 respectively, log-rank test). Vertical bars represent 95% confidence intervals. temic immunity. As shown in the in vivo depletion experiments, both NK cells and CD8+ T cells were essential for the initial antitumor effect with CD8+ T cells essential for the generation of a long-term systemic antitumor immunity. Depletion of either cell subset at the time of gene treatment led to rapid death of the NK cell-or CD8+ T-cell-depleted animals because of tumor progression (Fig. 3) . In accordance, NK cell or T-cell depletion at the time of subcutaneous challenge with parental MCA26 cells resulted in tumor growth in 78%-100% of long-term surviving animals after treatment with the combination IL-12/4-1BBL (Fig. 4, A) . In contrast to the strong initial antitumor effect mediated by NK cells, CD8+ T cells played the central role in long-term antitumor immunity when the pattern of subcutaneous tumor growth was analyzed in both groups. A clear trend, albeit not statistically significant (P ‫ס‬ .041), indicated that NK cells may play a role in the persistence of antitumor immunity. Compared with Tcell-depleted mice, tumors in NK celldepleted animals grew much more slowly. However, the subcutaneous tumor regressed after initial progression in three of nine animals in the NK cell-depleted group. These results stressed the critical role of CD8+ T cells in the long-term antitumor immunity induced by the combination IL-12/4-1BBL therapy. In vivo depletion of CD4+ T cells before IL-12 and 4-1BBL gene treatment of MCA26 liver tumors did not affect long-term survival, although, CD4+ T cells did not appear to be essential in the initial antitumor response.
In our study, 4-1BBL alone could not achieve long-term survival, while IL-12 alone did so in 20%-30% of tumorbearing animals in our liver metastasis model. In contrast, the combination IL-12/4-1BBL achieved long-term survival in 62% of the treated animals. IL-12 and 4-1BBL in combination act synergistically and had a better efficacy than either treatment alone. Moreover, as shown in the subcutaneous challenge of long-term surviving animals with parental and nonrelated tumor cells, the induced systemic antitumor immunity is persistent and specific. The mechanism of action of the combination IL-12/4-1BBL at the cellular level is not known. Schematically, IL-12 stimulates principally NK cells, while 4-1BBL induces proliferation of activated T cells. As shown previously (36), 4-1BB is expressed at the surface of activated NK cells. Engagement of 4-1BB by anti-4-1BB agonistic antibody or 4-1BBL was not followed by any NK cytolytic activity but seemed to induce an immunomodulatory function of NK cells. The effect of 4-1BBL on IL-12-activated NK cells and vice versa is not known, although the main immune effector cells explaining the synergistic action of IL-12 and 4-1BBL could be the NK cells that could be triggered either by engagement of 4-1BB or by T cells. By secreting cytokines like IL-12, granulocyte-macrophage colonystimulating factor, or IFN ␥ or through cell-to-cell contact, NK cells could potentiate the induced immune response by stimulating antigen-presenting cells and T cells (37) .
In conclusion, adenoviral-mediated intratumoral delivery of IL-12 and 4-1BBL genes in combination could represent a future treatment modality for metastatic colon carcinoma in humans. were injected subcutaneously and the kinetics of tumor growth was registered in four groups: group 1 (") ‫ס‬ natural killer (NK)-cell depletion (with anti-asialo GM1 antibody) (n ‫ס‬ 9); group 2 () ‫ס‬ total T-cell-depletion (with Thy-1.2 antibody) (n ‫ס‬ 5); group 3 (᭡) ‫ס‬ control immunoglobulin (Ig) (n ‫ס‬ 7); and group 4 (ࡗ) ‫ס‬ naive animals (n ‫ס‬ 7). A) Percentage of mice with tumor formation. One of seven animals formed a small and slow-growing tumor in the control Ig group. All naive and T-cell-depleted mice grew tumors. Compared with the control Ig group, the differences are statistically significant (P ‫ס‬ .015, Fisher's exact test). Seven of nine NK cell-depleted animals grew tumors. This was not significantly different from the control Ig group (P ‫ס‬ .041) after adjustment for multiple comparisons. Vertical bars represent 95% confidence intervals. B) Kinetics of tumor growth. * ‫ס‬ a statistically significant difference in average total tumor volume (ATTV) from the control Ig group at the P<.002 level by the Dunn multiple comparisons procedure for the Kruskal-Wallis test. The ATTV equals the area under the curve (AUC) of the tumor volumes over time for each mouse divided by the number of days (AUC/21). Error bars represent standard deviations.
